| Document |
Document Title |
|
WO/2023/027336A1 |
The present specification relates to: a heterocyclic compound represented by chemical formula 1; and an organic light-emitting device comprising same.
|
|
WO/2023/026884A1 |
To provide a curable composition that generates little outgas from an obtained cured product. The curable composition includes a radical polymerization initiator represented by formula 1 and a radical polymerizable compound. In formula 1...
|
|
WO/2023/028564A1 |
The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to indoline inhibitors of KIF18A and ...
|
|
WO/2023/026060A1 |
The present invention concerns Amyloid Binding Alcohol Dehydrogenase (ABAD) inhibitors (I) or (II) that interact non- competitively with nicotinamide adenine dinucleotide + H (NADH). Inhibition of ABAD is useful in the treatment or proph...
|
|
WO/2023/025602A1 |
The invention relates to compounds of formula I I wherein the variables have the meanings as defined in the specification, to compositions com-prising them, to active compound combinations comprising them, and to their use for protecting...
|
|
WO/2023/027327A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising the compound.
|
|
WO/2023/027479A1 |
The present application provides: a heterocyclic compound which can significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; and an organic light-emitting d...
|
|
WO/2023/027173A1 |
Provided are a compound represented by formula (1) (in formula (1), N*, R1-R9, L1, L2, L3, Ar1, and Ar2 are as defined in formula (1)), an organic electroluminescent element including the compound, and an electronic device including such...
|
|
WO/2023/022497A1 |
Provided are a novel compound of chemical formula I and a use thereof for preventing or treating SOS1-related diseases. A novel compound according to an aspect of the present invention inhibits interaction between SOS1 and a RAS family p...
|
|
WO/2023/020479A1 |
The present invention relates to a compound having a PARP7 inhibitory effect as shown in formula (I), and a pharmaceutically acceptable salt, a stereoisomer, a solvate, or a prodrug thereof, and use thereof and a preparation method there...
|
|
WO/2023/021012A1 |
Suggested are compositions comprising substituted azacycles on one hand and physiological cooling or warming agents, flavors and/or fragrances on the other for masking, enhancing and/or boosting flavors, improving soothing ability, and i...
|
|
WO/2023/020457A1 |
Provided herein are novel compounds, for example, compounds having a Formula (I), or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same. Also provided herein are methods of preparing the compou...
|
|
WO/2023/020534A1 |
Provided herein are compounds of Formula I, II, and III, which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds; pharmaceutical compositions comprising the compounds; as ...
|
|
WO/2023/022233A1 |
The present invention provides: a fused ring compound which has a high glass transition temperature; a charge transport material for photoelectric conversion elements for imaging elements or a charge blocking material for photoelectric c...
|
|
WO/2023/022480A1 |
The present application provides: a heterocyclic compound which can significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device; an organic light-emitting devic...
|
|
WO/2023/022417A1 |
Provided is a cyano group-substituted heteroaryl amine derivative which effectively absorbs high-energy external light source in the UV region to minimize damage to organic materials inside an organic electroluminescent device, thus cont...
|
|
WO/2023/016249A1 |
The present invention relates to a method for preparing a 3-aryloxy-3-five-membered heteroaryl-propylamine compound. Specifically, provided in the present invention is a method for preparing a compound of formula I. The method comprises ...
|
|
WO/2023/017699A1 |
The present invention addresses the problem of providing: a 3-substituted uracil compound that has excellent germicidal/antimicrobial activity and excellent safety, while being industrially beneficially synthesized; and an agricultural/h...
|
|
WO/2023/018052A1 |
Provided is a tertiary amine derivative, which effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials in an organic electroluminescent device, and thus contributes to a substa...
|
|
WO/2023/018040A1 |
Provided is a cyano group-substituted carbazole derivative, which effectively absorbs high energy external light source in a UV range so as to minimize damage to organic materials in an organic electroluminescent device, and thus contrib...
|
|
WO/2023/016434A1 |
Provided are compounds of formula (I) which can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. Also provided are pharmaceutical compositions compr...
|
|
WO/2023/019166A1 |
Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), a...
|
|
WO/2023/011028A1 |
The present invention relates to an organic compound, an electronic component and an electronic device. The structural formula of the organic compound of the present invention is represented by formula (I), and when used in an organic el...
|
|
WO/2023/013615A1 |
The present invention provides: an amine compound which suppresses a transverse current of an organic electroluminescent element; a hole injection layer which uses this amine compound; and an organic electroluminescent element which has ...
|
|
WO/2023/013900A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting element comprising the compound.
|
|
WO/2023/011608A1 |
The present application relates to a regulator containing a tricyclic derivative, a preparation method therefor and an application thereof, and in particular to a compound represented by general formula (Ia), a preparation method therefo...
|
|
WO/2023/013996A1 |
The present invention relates to a composition of chemical formula 1, a preparation method therefor, a pharmaceutical composition comprising same as an active ingredient, and a use thereof. The compound represented by chemical formula 1 ...
|
|
WO/2023/011656A1 |
A fluorescent dye as represented by formula (I), and a preparation method therefor and the use thereof. The fluorescent dye comprises an electron donor part D, a conjugate system E and an electron acceptor part A. The fluorescent dye wit...
|
|
WO/2023/007184A1 |
The present invention relates to compounds of Formulae (IA), (IB), (IIA), and (IIB) or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, optical isomer, N-oxide, and/or prodrug thereof. The invention also relates to the pro...
|
|
WO/2023/004914A1 |
A purification method for sertaconazole nitrate, which is used for preparing a sertaconazole nitrate crystal form with a melting point of 156-161°C. The purification method comprises: (1) mixing a crude product of sertaconazole nitrate ...
|
|
WO/2023/008895A1 |
The present invention relates to an organic compound which is used for an organic layer, such as an electron blocking layer or a hole transport layer, in an organic light-emitting device. By virtue of the structural characteristics posse...
|
|
WO/2023/004915A1 |
A preparation method for a sertaconazole nitrate crystal form, which is used for preparing a sertaconazole nitrate crystal form having a melting point of 156-161°C and which comprises the following steps: A. mixing a crude product of se...
|
|
WO/2023/008795A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2023/003234A1 |
The present invention provides: a novel compound capable of improving the luminous efficiency, stability and lifespan of an element; an organic electric element using same; and an electronic device thereof.
|
|
WO/2023/003014A1 |
The present disclosure provides, for example, a method for producing 2-(4-cyclopropyl-2-fluoroanilino)-3,4-difluoro-5-[[3-fluoro-
2-(methylsulfamoylamino)pyridin-4-yl]methyl]benzamide or a pharmacologically acceptable salt thereof, or a ...
|
|
WO/2023/003313A1 |
The present invention relates to: an organic compound which is used for an organic layer, such as a hole transport layer or an electron blocking layer, in an organic light-emitting device; and an organic light-emitting device comprising ...
|
|
WO/2023/003002A1 |
The present invention addresses the problem of providing a pharmaceutical composition, in particular, a compound suitable for preventing and/or treating inflammatory diseases and/or neurodegenerative diseases. The inventors of the pres...
|
|
WO/2023/002443A1 |
The disclosure provides compounds of Formula (I): (I) as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certai...
|
|
WO/2023/002165A1 |
P324681WO 319 ABSTRACT INHIBITOR COMPOUNDS The present invention relates to compounds of Formula (I) that target the MLH1 or MLH1 and PMS2 proteins that are components of the DNA Mismatch Repair (MMR) process: Formula (I) wherein R6, Y1,...
|
|
WO/2023/001794A1 |
There are disclosed certain substituted pyrazine-2-carboxamides of Formula (I), and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are inhibitors of hematopoi...
|
|
WO/2023/000834A1 |
Provided in the present invention are a benzimidazole or azabenzimidazole-6-carboxylic acid compound and the use thereof, which benzimidazole or azabenzimidazole-6-carboxylic acid compound has a structure as shown in formula (I). The ben...
|
|
WO/2023/284022A1 |
Provided are a phenanthroimidazole derivative, and a preparation method therefor and an application thereof. The phenanthroimidazole derivative has a structural formula as shown in formula (I), R being an electron donor group, wherein by...
|
|
WO/2023/282484A1 |
The present invention relates to a heterocyclic compound represented by formula 1, an organic light-emitting device comprising same, and a composition for an organic layer.
|
|
WO/2023/280970A1 |
The present invention relates to novel inhibitors of α-hemolysin of formula (I) and the use thereof for the prophylaxis and treatment of infections caused by Staphylococcus aureus; especially S. aureus lung infections.
|
|
WO/2023/283338A1 |
Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammato...
|
|
WO/2023/282676A1 |
The present specification relates to a compound and an organic light-emitting element comprising same.
|
|
WO/2023/282236A1 |
This rare earth complex is represented by a general formula (1). (In the formula, HC is a quinolinonato ligand and cumalinato ligand; L1 is a nitrogen-containing ligand, etc.; L2 is water, etc.; XL is a halide ion, etc.; M3+ is a trivale...
|
|
WO/2023/281271A1 |
There is provided pharmaceutical compounds of formula I, wherein R1, R2, R3, R4, R5, R6, Y1, Y2, Y3, X and Z have meanings given in the description, which compounds are useful in the treatment of autoimmune and/or fibrotic diseases, incl...
|
|
WO/2023/279986A1 |
A compound of formula I and a use thereof as an MALT1 inhibitor, and a pharmaceutical composition containing the compound. The compound can be used to treat diseases or disorders such as cancer.
|
|
WO/2023/279280A1 |
Disclosed in the present invention are an inhibitor of 1-methyl-7-chloro-4-((methoxyaryl heteroyl)amino)-N-(arylsulfonyl)-indole-2-carboxamide FBPase having a novel structure, a preparation method therefor, and a pharmaceutical compositi...
|
